Modulation of GSK-3 as a therapeutic strategy on Tau pathologies
Glycogen synthase kinase 3 (GSK-3) is ubiquitously expressed and unusually active in resting, non-stimulated cells. In mammals, at least three proteins (, and generated from two different genes, gsk3 and gsk3 are widely expressed at both the RNA and protein levels although some tissues...
Main Authors: | Miguel eMedina, Juan Jose eGarrido, Francisco G Wandosell |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2011-10-01
|
Series: | Frontiers in Molecular Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fnmol.2011.00024/full |
Similar Items
-
GSK-3 and Tau: A Key Duet in Alzheimer’s Disease
by: Carmen Laura Sayas, et al.
Published: (2021-03-01) -
Morin attenuates tau hyperphosphorylation by inhibiting GSK3β
by: Eun Ji Gong, et al.
Published: (2011-11-01) -
GSK-3β, a pivotal kinase in Alzheimer disease
by: Maria eLLorens-Martin, et al.
Published: (2014-05-01) -
Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits
by: Elena Gómez de Barreda, et al.
Published: (2010-03-01) -
Overexpression of GSK-3β in Adult Tet-OFF GSK-3β Transgenic Mice, and Not During Embryonic or Postnatal Development, Induces Tau Phosphorylation, Neurodegeneration and Learning Deficits
by: Alberto Rodríguez-Matellán, et al.
Published: (2020-09-01)